CD19 and precursor B-cell acute lymphoblastic leukemia: Patients with relapsed refractory B-cell acute lymphoblastic leukaemia were treated with CD19-specific CAR T-cells that had a greater than 40-fold reduction in affinity compared to gold standard FMC63 scFv-containing CARs.